These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12127866)

  • 21. Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
    Sohn SK; Moon JH; Cho YY; Chae YS; Kim JG; Lee KS; Hong SP; Kim SO
    Leuk Lymphoma; 2007 Aug; 48(8):1659-61. PubMed ID: 17701605
    [No Abstract]   [Full Text] [Related]  

  • 22. Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back.
    Alwan AF; Matti BF; Naji AS; Muhammed AH; Abdulsahib MA
    Leuk Lymphoma; 2014 Dec; 55(12):2830-4. PubMed ID: 24628295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.
    Jung AG; Horny HP; Sotlar K; Overbeck T; Schön MP; Lippert U
    J Am Acad Dermatol; 2011 Jul; 65(1):224-6. PubMed ID: 21679828
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical benefit of intermittent administration of imatinib in a patient with metastatic gastrointestinal stromal tumour.
    Morabito A; Longo R; Carillio G; Bonginelli P; Vitale S; Gasparini G
    Clin Oncol (R Coll Radiol); 2005 Apr; 17(2):96-7. PubMed ID: 15830571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ongoing challenges of a global international patient assistance program.
    Lassarat S; Jootar S
    Ann Oncol; 2006 Jun; 17 Suppl 8():viii43-viii46. PubMed ID: 16801339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
    Friedrich MJ
    J Natl Cancer Inst; 2003 Aug; 95(15):1102-3. PubMed ID: 12902432
    [No Abstract]   [Full Text] [Related]  

  • 27. Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts.
    Silberman S; Joensuu H
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S66-9. PubMed ID: 12528775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pregnancies in patients with chronic myeloid leukemia in the era of imatinib.
    Koh LP; Kanagalingam D
    Int J Hematol; 2006 Dec; 84(5):459-62. PubMed ID: 17189230
    [No Abstract]   [Full Text] [Related]  

  • 29. Promising clinical trials on kinase inhibitor.
    de Boer J
    Trends Cell Biol; 2001 Mar; 11(3):110. PubMed ID: 11306264
    [No Abstract]   [Full Text] [Related]  

  • 30. [Chronic myeloid leukemia and tyrosine kinase inhibitors].
    Mahon FX
    Rev Med Interne; 2001 Sep; 22(9):894-9. PubMed ID: 11599196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA licences imatinib mesylate for CML.
    Habeck M
    Lancet Oncol; 2002 Jan; 3(1):6. PubMed ID: 11905608
    [No Abstract]   [Full Text] [Related]  

  • 33. Irreversible imatinib-induced pneumonitis following long-term imatinib administration.
    Seki N; Ito A; Watanabe K; Shibakuki R; Seto T; Uematsu K; Mine T; Eguchi K
    Intern Med; 2007; 46(23):1941-2. PubMed ID: 18057772
    [No Abstract]   [Full Text] [Related]  

  • 34. Imatinib mesylate (Gleevec) in the treatment of 2 patients with Philadelphia-positive ALL relapsing after allogeneic stem cell transplantation.
    Sugimoto K; Mikoshiba M; Ohashi K; Akiyama H; Sakamaki H
    Int J Hematol; 2002 May; 75(4):440-2. PubMed ID: 12041679
    [No Abstract]   [Full Text] [Related]  

  • 35. Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome.
    Pieri L; Bosi A; Vannucchi AM
    Ann Hematol; 2010 Jul; 89(7):745-6. PubMed ID: 19953254
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of lower dose of imatinib to CML patients.
    Horikoshi A; Takei K; Sawada S
    Leuk Res; 2003 Dec; 27(12):1167. PubMed ID: 12921957
    [No Abstract]   [Full Text] [Related]  

  • 37. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec).
    Drummond A; Micallef-Eynaud P; Douglas WS; Hay I; Holyoake TL; Drummond MW
    Br J Haematol; 2003 Mar; 120(5):911-3. PubMed ID: 12614232
    [No Abstract]   [Full Text] [Related]  

  • 38. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
    Larmonier N; Janikashvili N; LaCasse CJ; Larmonier CB; Cantrell J; Situ E; Lundeen T; Bonnotte B; Katsanis E
    J Immunol; 2008 Nov; 181(10):6955-63. PubMed ID: 18981115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?
    Miyazawa K; Nishimaki J; Katagiri T; Sashida G; Shoji N; Kawakubo K; Suzuki A; Shimamoto T; Gotoh A; Kuriyama Y; Ito Y; Tauchi T; Kawanishi Y; Kimura Y; Ohyashiki K
    Int J Hematol; 2003 Jan; 77(1):93-5. PubMed ID: 12568307
    [No Abstract]   [Full Text] [Related]  

  • 40. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats.
    Lachowicz JL; Post GS; Brodsky E
    J Vet Intern Med; 2005; 19(6):860-4. PubMed ID: 16355681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.